194 patents
Page 7 of 10
Utility
Compositions and Methods for Gene Editing by Targeting Transferrin
19 Aug 21
Provided include compositions, methods, and systems for modulating the expression, function, and/or activity of a target gene, for example a blood-clotting protein such as Factor VIII (FVIII), in a cell by genome editing.
Alan Richard Brooks, Karen VO
Filed: 11 Jan 19
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
19 Aug 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
Methods and Compositions for Treating Cancer
12 Aug 21
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 23 Apr 21
Utility
Materials and methods for treatment of hereditary haemochromatosis
10 Aug 21
Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
Filed: 16 Mar 17
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
5 Aug 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander TERRETT, Demetrios KALAITZIDIS, Lawrence KLEIN
Filed: 12 Apr 21
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
5 Aug 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
Anti-bcma Car-t-cells for Plasma Cell Depletion
29 Jul 21
The present application relates to compositions and methods for controlled plasma cell depletion, such as for the treatment of various diseases and conditions associated with plasma cells.
Gregory COST
Filed: 26 Apr 19
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
27 Jul 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 15 Jun 20
Utility
Materials and methods for treatment of usher syndrome type 2A
27 Jul 21
The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell.
Albena Kantardzhieva, Akiko Noma, Abraham Scaria
Filed: 18 Jun 20
Utility
Compositions and Methods for Gene Editing for Hemophilia a
24 Jun 21
Provided include materials and methods for treating Hemophilia A in a subject ex vivo or in vivo.
Alan Richard Brooks
Filed: 17 Oct 18
Utility
Compositions and Methods for Genomic Editing by Insertion of Donor Polynucleotides
10 Jun 21
The present disclosure provides donor polynucleotides, genome editing systems, methods, and kits which correct or induce a mutation in a gDNA.
Troy Dean CARLO, Roman Lvovitch BOGORAD
Filed: 18 Feb 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
25 May 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 3 Aug 20
Utility
Universal donor cells
18 May 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 14 Jul 20
Utility
Universal donor cells
18 May 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 14 Jul 20
Utility
Manufacturing Process for Making T Cells Expressing Chimeric Antigen Receptors
13 May 21
Aspects of the present disclosure relate to methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that provide several improvements over conventional manufacturing methods, thereby enabling production of a robust supply of clinically useful CAR T-cell therapies.
Hui Yu, Demetrios Kalaitzidis, Siyuan Tan
Filed: 13 Nov 20
Utility
Methods of Manufacturing Car-t Cells
13 May 21
Aspects of the present disclosure relate to methods for manufacturing genetically engineered T cells expressing a chimeric antigen receptor (CAR) that provide several improvements over conventional manufacturing methods, thereby enabling production of a robust supply of clinically useful CAR T-cell therapies.
Julie Carson, Demetrios Kalaitzidis, Siyuan Tan, Hui Yu
Filed: 13 Nov 20
Utility
Compositions and Methods for Gene Editing by Targeting Fibrinogen-alpha
6 May 21
Provided include compositions, methods, and systems for modulating the expression, function, and/or activity of a target gene, for example a blood-clotting protein such as Factor VIII (FVIII), in a cell by genome editing.
Alan Richard Brooks
Filed: 15 Feb 19
Utility
Materials and methods for treatment of autosomal dominant cone-rod dystrophy
4 May 21
The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell.
Ryo Takeuchi, Akiko Noma, Shuying He, Abraham Scaria
Filed: 12 Jun 20
Utility
Universal Donor Cells
22 Apr 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 14 Jul 20
Utility
Materials and Methods for Engineering Cells and Uses Thereof In Immuno-oncology
25 Mar 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 29 Sep 20